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The treatment recommendations in obsessive-compulsive disorder (OCD) after lack of response to selective serotonin reuptake
inhibitors (SSRIs) include augmentation with other drugs, particularly clomipramine, a more potent serotonin reuptake inhibitor
(SRI), or antipsychotics.We present two cases of response to lamotrigine augmentation in treatment-refractoryOCD; each received
multiple SRI trials over a >10-year period. The first patient had eleven years of treatment with multiple combinations including
clomipramine and SSRIs. She had a >50% decrease of Y-BOCS (from 29 to 14) by augmenting paroxetine (60mg/day) with
lamotrigine (100mg/day). The second patient had 22 years of treatment with multiple combinations, including combinations of
SSRIs with clomipramine and risperidone. She had an almost 50% decrease of Y-BOCS (from 30 to 16) and disappearance of
tics by augmenting clomipramine (225mg/d) with lamotrigine (200mg/day). These two patients were characterized by lack of
response to multiple treatments, making a placebo response to lamotrigine augmentation unlikely. Prospective randomized trials
in treatment-resistant OCD patients who do not respond to combinations of SSRIs with clomipramine and/or antipsychotics are
needed, including augmentation with lamotrigine. Until these trials are available, our cases suggest that clinicians may consider
lamotrigine augmentation in such treatment-resistant OCD patients.
1. Introduction
There is general agreement in the obsessive-compulsive dis-
order (OCD) literature that the first line for pharmacolog-
ical treatment is the selective serotonin reuptake inhibitors
(SSRIs). This is supported by practical guidelines [1], meta-
analysis [2], and treatment algorithms [3]. The recommen-
dations after lack of response to SSRIs are not so well estab-
lished but usually include augmentation with other drugs:
(1) particularly clomipramine, a more potent serotonin reup-
take inhibitor (SRI), or (2) antipsychotics [1–6]. More recent-
ly, augmentation with glutamatergic agents has also been
recommended [3].
Lamotrigine is an antiepileptic drug and mood stabilizer
that has antiglutamatergic properties [7] and has been occa-
sionally used in OCD treatment. Two small open studies
used lamotrigine for treating obsessive symptoms, one in
schizophrenia [8] and another in bipolar disorder [9]. A small
open study [10] of augmentation of SRIs with 100mg/day of
lamotrigine in 8 patients reported negative results. A case
report [11] of lamotrigine augmentation using up to 150mg/
day in a patient with a stable dose of clomipramine (225mg/
day) described a remarkable improvement. Bruno et al. [12]
conducted a 16-week double-blind, randomized, and pla-
cebo-controlled trial of lamotrigine augmentation (up to 100
mg/day) in patients receiving SSRIs. The patient had an
adequate SSRI trial for at least 12 weeks and was still having
enoughOCD symptoms, as determined by a Yale-BrownOb-
sessive-Compulsive Scale [13, 14] (Y-BOCS) score >16. This
scale has a possible range of 0 to 40. At the end of the study,
85% (17/20) of the lamotrigine patients met response criteria
of 25% improvement or greater in Y-BOCS total score com-
pared with baseline versus none in the 20 placebo patients.
2 Case Reports in Psychiatry
Here, we describe two cases of marked response to lam-
otrigine augmentation in open treatment, assessed by the
same psychiatrist (the first author). These two cases are im-
portant because they include patients who were treatment-
refractory and received multiple SRIs trials over a >10-year
period, making the possibility of placebo response unlikely.
2. Case Presentations
2.1. Case 1. This was a 24-year-old Spanish woman with fam-
ily history of bipolar disorder on her maternal side. She ret-
rospectively reported that her first symptoms started at the
age of 8 when she had an obsessive fear that something would
happen to her mother. At 12 years of age she was diagnosed
with OCD; at that time she had developed religious obses-
sions and compulsions to kiss saints’ pictures to avoid some-
thing wrong happening. During these 11 years, medications
used included clomipramine (up to 225mg/day), fluoxetine
(up to 60mg/day), fluvoxamine (up to 200mg/day), paroxe-
tine (up to 60mg/day), lithium (up to 400mg/day), bupro-
pion (up to 300mg/day), and unknown doses of buspirone,
clonazepam, and lorazepam. She visited different psychia-
trists in different areas of Spain, including an outpatient clinic
specialized in OCD treatment.
At the first visit she had a Y-BOCS score of 29 in spite
of cognitive behavioral therapy (CBT) and pharmacological
treatment with paroxetine (40mg/day), lithium (400mg/
day), and clonazepam (1mg at night). The predominant
symptoms were obsessions of an aggressive, religious, and
sexual nature.Thepsychiatrist proposed lithiumdiscontinua-
tion, an increase of paroxetine to 60mg/day, and the addition
of lamotrigine 25mg/day in the first week with an increase of
25mg/week to reach a dose of 100mg/day in 4 weeks. After
5 weeks, at the second visit the patient was taking paroxetine
(60mg/day), lamotrigine (100mg/day for 1 week), and clon-
azepam (1mg at night). She had a remarkable improvement
with a reduction>50% and a total Y-BOCS score of 14. Twelve
weeks after the initial visit, at the third visit with the same
CBT and pharmacological treatment, the patient reported a
worsening of OCD symptoms (Y-BOCS total score = 19) due
to psychosocial stressors (family problems and university
exams). Due to her anxiety she had started to pinch her skin
when her guilt feelings were worse. The psychiatrist added
50mg/day of quetiapine-extended release. Sixteenweeks after
the initial visit, at the fourth visit with the same CBT and tak-
ing paroxetine (60mg/day), lamotrigine (100mg/day), clon-
azepam (1mg at night), and quetiapine-extended release (50
mg/day), the patient reported an improvement, the disap-
pearance of anxiety associatedwith a decrease in psychosocial
stress. The psychiatrist discontinued the quetiapine. Twenty-
four weeks after the initial visit, at the fifth visit with the
same CBT and taking paroxetine (60mg/day), lamotrigine
(100mg/day), and clonazepam, the patient reported a com-
plete disappearance of psychosocial stressors and improve-
ment in OCD symptoms (Y-BOCS total score = 14). The pa-
tient reported that lamotrigine had helped more than any
other treatment, and she had never felt as well since she start-
ed treatment at the age of 12. After another year of follow-
up (1 year and 7 months after the initial visit), the patient
continued to report mild OCD chronic symptoms with
limited functional impairment to the point that the patient
has been able to work for three months in another country,
proving to herself that she can be an autonomous person in
spite of her illness. As the patient is very insightful about her
illness and treatment response, the psychiatrist asked her, on
a Likert scale of 0–10, to rate lamotrigine’s contribution to her
improvement, and she responded 7 to 8.
2.2. Case 2. This was a 46-year-old Spanish woman. She had
no medical problems and no family history of psychiatric
disorder. She had been diagnosed 22 years earlier and had
received multiple treatments including fluoxetine (up to
60mg/day), paroxetine (up to 40mg/day), and bromazepam.
At the age of 43 she was taking clomipramine (225mg/day)
and fluvoxamine (200mg/day); risperidone (0.5mg/day) was
added. The patient took this combination for at least 6
months, and then she decided to discontinue risperidone due
to its lack of efficacy. Over the last two years she had received
the combination of clomipramine (225mg/day), fluvoxamine
(200mg/day), and alprazolam (2mg/day). She definitively
was a treatment-resistant case and had no response to risp-
eridone augmentation. As a matter of fact, with the then-
current treatment including relatively high doses of both
clomipramine andfluvoxamine, she had aY-BOCS total score
of 30 (possible range 0–40) [12, 13]. At that time, she had
intrusive and repetitive thoughts about negative events, fear
of hurting someone, and apprehension that something terri-
ble might occur. Her compulsions included frequent check-
ing rituals of the domestic gas valves or the house locks. She
also had motor tics (her shoulders moving up).
The patient agreed to a lamotrigine augmentation trial
after fluvoxamine discontinuation. Two weeks after fluvox-
amine was discontinued, lamotrigine was added to clomi-
pramine 225mg/day and alprazolam 2mg/day. The initial
lamotrigine dose was 25mg/day; it was increased 25mg
weekly until reaching 100mg/day. Five weeks after the first
lamotrigine dose and one week after reaching 100mg/day of
lamotrigine, she reported an improvement in compulsions,
obsessions, and tics. The patient was delighted with the re-
sponse and agreed to increase lamotrigine to 200mg/day. By
the time of the third visit, after 11weeks of the lamotrigine trial
and 5 weeks on the 200mg/day dose, the tics had completely
disappeared and the Y-BOCS score was 21. At the time of
the last evaluation, after five months on lamotrigine and 3.5
months on the 200mg/day dose, the tics continued to be
absent and the Y-BOCS score had decreased to 16. No sec-
ondary effects were reported. It is important to stress that
(1) the patient had 22 years of prior treatments including no
obvious response to combinations of SSRI plus clomipramine
and SSRI plus risperidone, making a placebo response to
lamotrigine augmentation unlikely, and (2) the response to
lamotrigine augmentation was dramatic with a 47% decrease
in Y-BOCS total score and disappearance of the tics.
3. Discussion
Two recent literature reviews [15, 16] of glutamatergic mech-
anisms in OCD describe why glutamatergic agents such as
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lamotrigine may help OCD. The list of glutamatergic drugs
tried in OCD includes riluzole [15, 16], memantine [15], ket-
amine [15], glycine [15], sarcosine [15], N-acetylcysteine [15,
16], D-cycloserine [15, 16], topiramate [15], and lamotrigine
[15, 16].
Wu et al. [16] summarized the prior literature on the
pivotal role of glutamate in corticostriatal-thalamocortical
(CSTC) models of OCD. One of the leading OCD models is
based on the balance between direct and indirect pathways
within CSTC circuits. According to this theory, reciprocal
interaction between direct (ultimately leads to thalamic stim-
ulation of the cortex) and indirect (ultimately leads to tha-
lamic inhibition of the cortex) pathways normally resulted
in a dynamic balance with no one pathway predominating.
Hyperactivity of the direct pathway or hypoactivity of the
indirect pathway would disinhibit CSTC circuits and pro-
mote consequent release of hardwired behaviors (compul-
sions) and cognitions (obsessions) that were normally held
in check.
The exact mechanism explaining why lamotrigine or
other glutamatergic agentsmay be good augmentation strate-
gies in OCD is not as important as the need for more pro-
spective well-controlled trials demonstrating whether lam-
otrigine may help in all treatment-resistant OCD or at least
in subgroups with glutamatergic abnormalities. OCD may
be a heterogeneous disorder, and not all patients may have
glutamatergic abnormalities [15]. In the first randomized,
placebo-controlled trial of lamotrigine augmentation, Bruno
et al. [12] studied patients for 16 weeks who were taking
up to 100mg/day of lamotrigine; their patients had lower
baseline Y-BOCS scores (mean 26) than our two patients. It
is important to stress that none of their placebo patients re-
sponded to placebo because moderate-to-severe OCD cases
are not likely to respond to placebo. Our two patients were
characterized by severe long-termOCDwith lack of response
to multiple treatments, making a placebo response to lamot-
rigine augmentation unlikely.
The first of our patients had multiple years of treatment
with multiple drug combinations including SSRIs and clomi-
pramine. She had more than 50% decrease in Y-BOCS score
by augmenting paroxetine with lamotrigine up to 100mg/day.
The second patient hadmultiple years of treatment with mul-
tiple combinations including the combination of SSRIs and
clomipramine and SSRIs and risperidone. After augment-
ing clomipraminewith lamotrigine up to 200mg/day, she had
almost a 50% decrease in Y-BOCS baseline score and disap-
pearance of tics.
Prospective randomized trials in patients such as those
presented in this paper with treatment-resistant OCD who
do not respond to combinations of SSRIs with clomipramine
and/or antipsychotics are needed. Lamotrigine may be an
ideal candidate for these trials.
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